Table 2 Summary of measurements at baseline (pre-CRRT)
Investigations | Units | Reference range | Number with abnormal results | Range of abnormal results | Mean/median |
|---|---|---|---|---|---|
Thrombin time | Ratio | (0.86–1.14) | 1 | 1.19 | N/A |
Classic APCR | Ratio | (3.3–5.82) | 3 | 2.22, 2.25, 2.44 | 2.30/2.25 |
Modified APCR | Ratio | (2.63–3.34) | 3 | 1.81,2.51, 2.53 | 2.28/2.51 |
Antithrombin activity | IU/dL | (85.9–117.5) | 9 | 24.2–80.0 | 61.8/67.4 |
Protein C activity | IU/dL | (77.1–126.4) | 9 | 38.5–72.5 | 58.3/61.5 |
Free protein S antigen | IU/dL | (80.2–137.4) | 5 | 48.9–76.2 | 67.7/70.4 |
Lupus anticoagulant by dRVVT and dAPTT | - | Not detected | 5 | 5 × positive | N/A |
IgG aCL | GPL U/mL | (0–10) | 3 | 11.2, 13.5, 17.2 | 14.0/13.5 |
IgM aCL | MPL U/mL | (0–10) | 3 | 19.2, 19.7, 31.9 | 23.6/19.7 |
IgG aβ2GPI | SGU | (0–2.9) | 3 | 3.9, 6.0, 8.6 | 6.2/6.0 |
IgM aβ2GPI | SMU | (0–6.5) | 7 | 6.8–31.9 | 15.0/12.0 |
Homocysteine | µmol/L | (0–15) | 5 | 15.2–18.0 | 16.1/15.6 |
VWF:GPIbR | IU/dL | (41–127) | 4 | 380.1–494.1 | 426.0/415.0 |
VWF:Ag | IU/dL | (50–172) | 11 | 280.8–682.7 | 531.3/581.3 |
FVIII:C | IU/dL | (50–150) | 11 | 199.4–614.4 | 418.4/432.6 |
Thrombin:antithrombin complexes (TAT) | µg/L | (1–4.1) | 7 | 9.22–74.6 | 24.3/25.1 |
Prothrombin fragment 1.2 | pmol/L | (69–229) | 3 | 333.3, 401.1, 964.0 | 566.1/401.1 |
Prothrombin 20,210 | – | – | 1 | 1 × heterozygous | N/A |
Factor V Leiden | – | – | 0 | – | – |